“童颜针”的好日子要到头了

Core Viewpoint - The article discusses the price war in the cosmetic injectables market, particularly focusing on the "童颜针" (youthful needle) products, highlighting the conflict between upstream material suppliers and downstream medical institutions over pricing strategies [1][3][34]. Group 1: Market Dynamics - New Oxygen's self-operated clinic is selling the "艾维岚" product at 5,999 yuan, which is one-third of the market price, leading to dissatisfaction from the brand owner, 圣博玛 [1][2]. - The price war is intensifying as more competitors enter the market, with several new products expected to launch soon [3][30][32]. - The market for "童颜针" is projected to grow from $1.488 billion in 2024 to $2.082 billion by 2033, indicating significant growth potential [25]. Group 2: Company Strategies - New Oxygen has established a strategic partnership with 东方妍美, securing exclusive rights to commercialize several upcoming products, including the XH301 [4][19]. - 东方妍美's XH301 is expected to complete domestic listing reviews in the second half of the year, with the potential to reverse its current financial losses [6][17]. - The company plans to adopt an agency sales model rather than direct sales, which is seen as a safer approach given its current financial situation [18][22]. Group 3: Product Insights - XH301, a key product from 东方妍美, utilizes a combination of 聚左旋乳酸 (PLLA) and 羧甲基纤维素 (CMC) to stimulate collagen regeneration, similar to the materials used in 艾维岚 [12][14]. - The product's unique manufacturing process aims to enhance safety and reduce adverse reactions, with clinical trials showing a 95.5% effectiveness rate in wrinkle correction [15][16]. - The competitive landscape is challenging, as the pricing of "童颜针" products is under pressure, with some institutions offering prices as low as 5,900 yuan [37][38].